


AUTOPHAGY, INFECTION, AND THE IMMUNE RESPONSE

Edited by William T. Jackson and Michele S. Swanson



WILEY Blackwell

AUTOPHAGY, INFECTION, AND THE IMMUNE RESPONSE



AUTOPHAGY, INFECTION, AND THE IMMUNE RESPONSE

EDITED BY

William T. Jackson and Michele S. Swanson

WILEY Blackwell



This edition first published 2015. © 2015 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey
Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Autophagy, infection, and the immune response / edited by William T. Jackson and Michele Swanson.
p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-118-67764-3 (cloth)

I. Jackson, William T., 1971- , editor. II. Swanson, Michele, editor.

[DNLM: 1. Autophagy-immunology. 2. Immune System Processes. 3. Immunity, Innate.

4. Virus Physiological Processes. QU 375]

QR181.7

616.07'9-dc23

2014029016

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

CONTENTS

Contributors	xiii
Preface	xvii
Acknowledgments	xix
1 AUTOPHAGY AND IMMUNITY	1
<i>Xu Liu and Daniel J. Klionsky</i>	
1.1 Introduction	1
1.2 Autophagy	2
1.2.1 Types of autophagy	2
1.2.2 Morphology	3
1.2.3 Molecular machinery	3
1.2.4 Physiological roles	5
1.3 Autophagy and immunity	6
1.3.1 Xenophagy: autophagic clearance of intracellular microorganisms	6
1.3.2 Autophagy and cryptides	9
1.3.3 Autophagy and pattern recognition receptors (PRRs)	9
1.3.4 Autophagy and MHC antigen presentation	10
1.3.5 Autophagy regulation by immune signaling molecules	11
1.3.6 Autophagy, inflammation, and autoimmunity	11
1.4 Conclusion	12
References	12
2 TECHNIQUES FOR STUDYING AUTOPHAGY	19
<i>Isei Tanida and Masato Koike</i>	
2.1 Introduction	19
2.2 Reagents and tools for studying autophagy	21
2.2.1 Reagents to monitor the lysosomal flux of LC3-II	21
2.2.2 Reagents that induce autophagy	21
2.2.3 Reagents and recombinant tools that inhibit autophagy	22
2.3 Detection of LC3-I AND LC3-II by immunoblotting	22
2.4 Immunofluorescent analyses of endogenous LC3	23
2.5 Monitoring autophagy using fluorescent protein-tagged LC3	23
2.6 Morphological analyses of autophagosomes and autolysosomes by TEM	24
2.6.1 Reagents or stock solutions	26
2.6.2 Resin embedding of cell pellets or microbes	26

2.6.3	Resin flat embedding of cells grown on glass or plastic coverslips	27
2.7	Techniques for immunoelectron microscopy	28
	References	29
3	ROLE OF AUTOPHAGY IN DNA VIRUS INFECTIONS <i>IN VIVO</i>	33
	<i>Xiaonan Dong and Beth Levine</i>	
3.1	Introduction	33
3.2	<i>In vivo</i> interplay between autophagy and DNA viruses in plants and invertebrates	34
3.3	<i>In vivo</i> interplay between autophagy and DNA viruses in vertebrates	35
3.3.1	Autophagy is an essential antiviral mechanism that protects against HSV-1 <i>in vivo</i>	35
3.3.2	The autophagy-HBV interplay <i>in vivo</i> : a balance between viral exploitation and tumor suppression	40
3.3.3	Autophagy may suppress γ -herpesvirus persistent infection	42
3.4	Conclusion	43
	Acknowledgments	44
	References	44
4	STUDYING RNA VIRUSES AND AUTOPHAGY <i>IN VIVO</i>	49
	<i>Mehrdad Alirezaei and J. Lindsay Whitton</i>	
4.1	Introduction	49
4.2	<i>In vivo</i> interactions between autophagy and RNA viruses in plants and invertebrates	50
4.2.1	Plants	50
4.2.2	Invertebrates	50
4.3	<i>In vivo</i> Interactions between autophagy and RNA viruses in vertebrates	51
4.3.1	Togaviridae	51
4.3.2	<i>Caliciviridae</i>	51
4.3.3	Orthomyxoviridae	53
4.3.4	Flaviviridae	53
4.3.5	Picornaviridae	54
4.4	Conclusion	62
	Acknowledgments	63
	References	63
5	AUTOPHAGY AND PICORNAVIRUS INFECTION	67
	<i>Tom Wileman, Zhigang Zhou, Matthew Whelband, Eleanor Cottam, Stephen Berryman, Terry Jackson and Rebecca Roberts</i>	
5.1	Introduction	67
5.2	Selective autophagy involves autophagy receptors with LC3-interacting domains	69
5.3	Autophagy is activated during virus infection	69
5.4	Picornaviruses and autophagy	69
5.4.1	Poliovirus	70
5.4.2	Coxsackievirus	72

5.4.3	Human enterovirus 71	73
5.4.4	Encephalomyocarditis virus	73
5.4.5	Foot-and-mouth disease virus	74
5.4.6	Human rhinoviruses	75
5.5	Caution in interpretation of induction of LC3 puncta and double-membraned vesicles in the context of autophagy	75
5.5.1	LC3 puncta	75
5.6	Conclusions and future research	77
	References	78
6	FLAVIVIRUSES AND AUTOPHAGY	81
	<i>Tristan X. Jordan and Glenn Randall</i>	
6.1	Introduction	81
6.1.1	Autophagy	81
6.2	Flaviviruses	83
6.3	Dengue virus	83
6.3.1	Autophagosomes as a platform for replication?	85
6.3.2	Modulation of lipid metabolism	86
6.3.3	Potential role for the autophagy-related proteins USP10 and USP13 in DENV virion maturation	87
6.3.4	Cytoprotective autophagy	88
6.3.5	The role of autophagy in an ADE model of monocyte infection	89
6.3.6	Autophagy in DENV infections in mice	89
6.4	Other Flaviviruses	90
6.4.1	Japanese encephalitis virus	90
6.4.2	Modoc virus	90
6.4.3	West Nile virus	90
6.5	Concluding remarks	92
	Acknowledgments	92
	References	93
7	AUTOPHAGY: A HOME REMODELER FOR HEPATITIS C VIRUS	101
	<i>Marine L.B. Hillaire, Elodie Décembre, and Marlène Dreux</i>	
7.1	Introduction	101
7.1.1	Autophagy	101
7.1.2	Hepatitis C virus (HCV) disease, genome and replication	103
7.2	HCV induces a proviral autophagy	111
7.3	How does HCV trigger autophagy vesicle accumulation?	111
7.4	Dynamic membrane remodeling by autophagy	113
7.5	Interlinkage of autophagy with the innate immune response	114
7.6	Autophagy and cell death	115
7.7	Removal of aberrant deposits and organelles by autophagy: implications for liver injury associated with chronic hepatitis C	116
7.7.1	Autophagy and lipid metabolism	116
7.7.2	Mitophagy and HCV persistence	117
7.8	Conclusions and future directions	118
	Acknowledgments	119
	References	119

8	MODULATING AUTOPHAGY TO CURE HUMAN IMMUNODEFICIENCY VIRUS TYPE-1	127
	<i>Stephen A. Spector and Grant R. Campbell</i>	
8.1	Introduction	127
8.2	HIV subverts autophagy to promote its own replication	129
8.3	HIV infection inhibits autophagy during permissive infection while induction of autophagy leads to inhibition of HIV	130
8.4	HIV-induced autophagy in bystander CD4 ⁺ T cells results in cell death	130
8.5	Modulation of autophagy as a mechanism for HIV-associated neurocognitive impairment	132
8.6	How can autophagy be exploited to control and eradicate HIV?	134
	Acknowledgments	137
	References	138
9	AUTOPHAGY IN THE INFECTED CELL: INSIGHTS FROM PATHOGENIC BACTERIA	143
	<i>Andrea Sirianni and Serge Mostowy</i>	
9.1	Introduction	143
9.2	Autophagy–bacteria interactions	143
9.2.1	<i>Salmonella typhimurium</i>	144
9.2.2	<i>Mycobacterium tuberculosis</i>	145
9.2.3	<i>Legionella pneumophila</i>	146
9.2.4	<i>Listeria monocytogenes</i>	147
9.2.5	<i>Shigella flexneri</i>	149
9.2.6	<i>Mycobacterium marinum</i>	150
9.3	Conclusions	151
	Acknowledgments	151
	References	152
10	Rab PROTEINS IN AUTOPHAGY: STREPTOCOCCUS MODEL	159
	<i>Takashi Nozawa and Ichiro Nakagawa</i>	
10.1	Introduction	159
10.2	Rab GTPase	160
10.3	Rab GTPases in starvation-induced autophagy	160
10.4	Rab localization in autophagy during <i>Streptococcus</i> infection	161
10.5	Involvement of Rab7 in the initial formation of GcAV	163
10.6	Requirement of Rab23 for GcAV formation	163
10.7	Facilitation by Rab9A of GcAV enlargement and lysosomal fusion	164
10.8	Conclusion and perspective	165
	References	167
11	HELICOBACTER PYLORI INFECTION CONTROL BY AUTOPHAGY	171
	<i>Laura K. Greenfield, Frances Dang, and Nicola L. Jones</i>	
11.1	<i>Helicobacter pylori</i>	171
11.2	<i>H. pylori</i> and evasion of host immune responses	176
11.3	Autophagy	178
11.4	Acute <i>H. pylori</i> infection: induction of autophagy in gastric epithelial cells	180

11.5	Chronic <i>H. pylori</i> infection: suppression of autophagy in gastric epithelial cells	184
11.6	<i>H. pylori</i> induction of autophagy in immune cells	185
11.7	Host genetics affecting autophagic clearance of <i>H. pylori</i>	185
11.8	<i>H. pylori</i> disrupted autophagy and gastric cancer	186
11.9	<i>H. pylori</i> therapy: is autophagy a contender?	187
11.10	Concluding remarks	188
	Acknowledgments	189
	References	189

12 INTERACTIONS BETWEEN SALMONELLA AND THE AUTOPHAGY SYSTEM **201**

Teresa L.M. Thurston and David W. Holden

12.1	Introduction	201
12.2	<i>Salmonella</i> 's life within the host	201
12.3	<i>Salmonella</i> 's survival in a harsh intracellular habitat	202
12.4	Models for studying <i>Salmonella</i> infection	203
12.5	Mechanisms of <i>Salmonella</i> autophagy	204
	12.5.1 <i>Salmonella</i> is targeted for antibacterial autophagy	204
	12.5.2 Antibacterial autophagy induction	205
	12.5.3 Eat-me signals for antibacterial autophagy	206
	12.5.4 Autophagy receptors provide cargo specificity	208
12.6	Autophagy of <i>Salmonella in vivo</i>	209
12.7	Bacterial countermeasures	210
	12.7.1 Could <i>Salmonella</i> counteract autophagy?	210
	12.7.2 Potential autophagy avoidance mechanisms	210
	12.7.3 SseL deubiquitinates autophagy-targeted protein aggregates	210
	12.7.4 Does <i>Salmonella</i> inhibit selective antibacterial autophagy?	211
12.8	Perspectives	211
	References	213

13 HOST FACTORS THAT RECRUIT AUTOPHAGY AS DEFENSE AGAINST TOXOPLASMA GONDII **219**

Carlos S. Subauste

13.1	Introduction	219
13.2	CD40, autophagy and lysosomal degradation of <i>T. gondii</i>	220
13.3	Events downstream of CD40 involved in the stimulation of autophagy	222
13.4	Relevance of autophagy during <i>in vivo</i> infection with <i>T. gondii</i>	224
13.5	IFN- γ and ATG5 in <i>T. gondii</i> infection	224
13.6	<i>T. gondii</i> manipulates host cell signaling to inhibit targeting by LC3 ⁺ structures and to maintain the nonfusogenic nature of the parasitophorous vacuole	227
13.7	Autophagy machinery within <i>T. gondii</i>	228
13.8	Conclusion	229
	Acknowledgments	229
	References	229

14	MYCOBACTERIUM TUBERCULOSIS AND THE AUTOPHAGIC PATHWAY	233
	<i>Gabriela María Recalde and María Isabel Colombo</i>	
14.1	<i>Mycobacterium tuberculosis</i> , a pathogen that resides in a self-tailored compartment to avoid killing by the host cell	233
14.2	The ESX-1 secretion system	235
14.3	<i>Mycobacterium marinum</i> , a close relative that escapes and forms actin tails in the cytoplasm	235
14.4	Mycobacterium actively modulates autophagy	236
14.5	Mycobacterium tuberculosis, a pathogen also able to escape toward the cytoplasm	239
14.6	Concluding remarks	240
	References	241
15	AUTOPHAGY ENHANCES THE EFFICACY OF BCG VACCINE	245
	<i>Arshad Khan, Christopher R. Singh, Emily Soudani, Pearl Bakhru, Sankaralingam Saikolappan, Jeffrey D. Cirillo, N. Tony Eissa, Subramanian Dhandayuthapani and Chinnaswamy Jagannath</i>	
15.1	Introduction	246
15.2	Induction of autophagy through mTOR enhances antigen presentation via the MHC-II pathway in macrophages and dendritic cells	247
15.2.1	Rapamycin-induced autophagy enhances antigen presentation in APCs	248
15.2.2	Rapamycin and Torin1-induced autophagy enhances both antigen presentation and IL-1 β secretion from BCG infected APCs	248
15.3	Intracellular mechanisms of autophagic routing of particulate BCG vaccine and secreted Ag85B into autophagosomes and enhanced MHC-II mediated antigen presentation	251
15.3.1	Overexpression of secreted Ag85B in BCG vaccine leads to aggresome formation in the cytosol of APCs	251
15.3.2	Overexpressed Ag85B from BCG vaccine forms aggresomes, which enhance antigen presentation through autophagy	251
15.3.3	Discussion: <i>in vitro</i> studies on autophagy and antigen presentation	253
15.4	Rapamycin activation of dendritic cells enhances efficacy of DC-BCG vaccine	255
15.4.1	Discussion	256
15.5	Rapamycin coadministration with BCG vaccine in mice enhances CD4 and CD8 T cell mediated protection against tuberculosis	256
15.5.1	Discussion	262
15.6	Conclusions	262
	Acknowledgments	263
	References	263

16	AUTOPHAGY'S CONTRIBUTION TO INNATE AND ADAPTIVE IMMUNITY: AN OVERVIEW	267
	<i>Christina Bell, Michel Desjardins, Pierre Thibault and Kerstin Radtke</i>	
16.1	Autophagy: different routes to the same goal?	267
16.2	Xenophagy: it is a dog-eat-dog world	269
16.3	Autophagy and Toll-like receptors: a mutual turn-on	269
16.4	Autophagy and antigen presentation: a cry for help to clear pathogenic invaders	270
16.5	Autophagy and inflammasomes: Mutual regulation for an effective immune response	273
16.6	Cross-talk between autophagy and cytokines	273
	Acknowledgments	275
	References	275
17	AUTOPHAGY IN IMMUNE RESPONSES TO VIRUSES	279
	<i>Christophe Viret and Mathias Faure</i>	
17.1	Innate immunity against viruses	279
17.2	Autophagy in antiviral innate immunity	281
17.2.1	Virus sensing for autophagy induction	281
17.2.2	Role of autophagy in xenophagy of viruses	282
17.2.3	Role of autophagy in antiviral innate immunity signaling	283
17.3	Autophagy manipulation by viruses to resist innate immunity	285
17.3.1	Autophagy manipulation by viruses to prevent IFN-I synthesis	285
17.3.2	Viruses subvert autophagy to interfere with inflammatory responses	286
17.3.3	Autophagy and cell death during virus infection	287
17.4	Autophagy in antiviral adaptive immunity	287
17.4.1	Promotion of adaptive immune responses to viral infection by autophagy	287
17.4.2	MHC class II-restricted presentation of viral epitopes	288
17.4.3	MHC class I-restricted presentation of viral epitopes	290
17.4.4	Autophagy and cross-presentation	292
17.5	Autophagy manipulation by viruses to escape adaptive immunity	294
17.5.1	MHC class II antigen presentation pathway	294
17.5.2	MHC class I antigen presentation pathway	295
17.5.3	Autophagy and antigen-presenting cell function	295
17.6	Concluding remarks	296
	Acknowledgments	296
	References	297
18	PROCESSING AND MHC PRESENTATION OF ANTIGENS AFTER AUTOPHAGY-ASSISTED ENDOCYTOSIS, EXOCYTOSIS, AND CYTOPLASM DEGRADATION	303
	<i>Christian Münz</i>	
18.1	Introduction	303
18.2	Substrate recognition by macroautophagy	305

18.3	Antigen processing for MHC class II presentation by macroautophagy	307
18.4	A role of macroautophagy in MHC class I antigen presentation	308
18.5	Antigen release by autophagy-assisted exocytosis	309
18.6	Autophagy-assisted phagocytosis	310
18.7	Conclusions and outlook	312
	Acknowledgments	312
	References	312
	Index	317

CONTRIBUTORS

Mehrdad Alirezaei Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA

Pearl Bakhru Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, Houston, Texas, USA

Christina Bell Proteomics and Mass Spectrometry Research Unit, Institute for Research in Immunology and Cancer, Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montreal, Quebec, Canada

Stephen Berryman The Pirbright Institute, Woking, Surrey, UK

Grant R. Campbell Department of Pediatrics, Division of Infectious Diseases, University of California, San Diego, La Jolla, California, USA

Jeffrey D. Cirillo Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Sciences Center—College of Medicine, College Station, Texas, USA

María Isabel Colombo Laboratorio de Biología Celular y Molecular, Instituto de Histología y Embriología (IHEM)-CONICET, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina

Eleanor Cottam The Pirbright Institute, Woking, Surrey, UK

Frances Dang Departments of Paediatrics and Physiology, University of Toronto, Cell Biology Program, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada

Elodie Décembre CIRI, Université de Lyon, Lyon, France; Inserm, Lyon, France; Ecole Normale Supérieure de Lyon, Lyon, France; Université Claude Bernard Lyon 1, Lyon, France; CNRS, Lyon, France; LabEx Ecofect, Université de Lyon, Lyon, France

Michel Desjardins Department of Pathology and Cell Biology, Université de Montreal, Montreal, Quebec, Canada

Subramanian Dhandayuthapani Center of Excellence for Infectious Diseases, Department of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech Health Sciences Center, El Paso, Texas, USA

Xiaonan Dong Center for Autophagy Research and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Marlène Dreux CIRI, Université de Lyon, Lyon, France; Inserm, Lyon, France; Ecole Normale Supérieure de Lyon, Lyon, France; Université Claude Bernard Lyon 1, Lyon, France; CNRS, Lyon, France; LabEx Ecofect, Université de Lyon, Lyon, France

- N. Tony Eissa** Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
- Mathias Faure** International Center for Infectiology Research (CIRI), CNRS, Université Claude Bernard Lyon 1, Université de Lyon, Ecole Normale Supérieure de Lyon, Lyon, France
- Laura K. Greenfield** Departments of Paediatrics and Physiology, University of Toronto, Cell Biology Program, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada
- Marine L.B. Hillaire** CIRI, Université de Lyon, Lyon, France; Inserm, Lyon, France; Ecole Normale Supérieure de Lyon, Lyon, France; Université Claude Bernard Lyon 1, Lyon, France; CNRS, Lyon, France; LabEx Ecofect, Université de Lyon, Lyon, France
- David W. Holden** MRC Centre for Molecular Bacteriology and Infection, Section of Microbiology Imperial College London, London, UK
- Terry Jackson** The Pirbright Institute, Woking, Surrey, UK
- Chinnaswamy Jagannath** Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, Houston, Texas, USA
- Nicola L. Jones** Departments of Paediatrics and Physiology, University of Toronto, Cell Biology Program, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada
- Tristan X. Jordan** Department of Microbiology, The University of Chicago, Chicago, Illinois, USA
- Arshad Khan** Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, Houston, Texas, USA
- Daniel J. Klionsky** Life Sciences Institute and Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, Michigan, USA
- Masato Koike** Department of Cell Biology and Neuroscience, Juntendo University School of Medicine, Tokyo, Japan
- Beth Levine** Center for Autophagy Research, Department of Microbiology, Department of Internal Medicine and Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas, USA
- Xu Liu** Life Sciences Institute and Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, Michigan, USA
- Serge Mostowy** Section of Microbiology, MRC Centre for Molecular Bacteriology and Infection, Imperial College London, London, UK
- Christian Münz** Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland
- Ichiro Nakagawa** Department of Microbiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
- Takashi Nozawa** Department of Microbiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
- Kerstin Radtke** Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montreal, Quebec, Canada
- Glenn Randall** Department of Microbiology, The University of Chicago, Chicago, Illinois, USA

- Gabriela María Recalde** Laboratorio de Biología Celular y Molecular, Instituto de Histología y Embriología (IHEM)-CONICET, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina
- Rebecca Roberts** Department of Infection and Immunity, Sheffield University, Sheffield, UK
- Sankaralingam Saikolappan** Center of Excellence for Infectious Diseases, Department of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech Health Sciences Center, El Paso, Texas, USA
- Christopher R. Singh** Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, Houston, Texas, USA
- Andrea Sirianni** Section of Microbiology, MRC Centre for Molecular Bacteriology and Infection, Imperial College London, London, UK
- Emily Soudani** Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, Houston, Texas, USA
- Stephen A. Spector** Department of Pediatrics, Division of Infectious Diseases, University of California, San Diego, La Jolla and Rady Children's Hospital, San Diego, California, USA
- Carlos S. Subauste** Division of Infectious Diseases and HIV Medicine, Department of Medicine, Department of Ophthalmology and Visual Sciences, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
- Isei Tanida** Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan
- Pierre Thibault** Proteomics and Mass Spectrometry, Research Unit, Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec, Canada
- Teresa L. M. Thurston** MRC Centre for Molecular Bacteriology and Infection, Section of Microbiology, Imperial College London, London, UK
- Christophe Viret** International Center for Infectiology Research (CIRI), CNRS, Université Claude Bernard Lyon 1, Université de Lyon, Ecole Normale Supérieure de Lyon, Lyon, France
- Matthew Whelband** Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK
- J. Lindsay Whitton** Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA
- Tom Wileman** Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK
- Zhigang Zhou** Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK

PREFACE

Since the discovery nearly 20 years ago that pathogenic bacteria and viruses intimately associate with autophagosomal membranes, scientists have determined that autophagy is a critical component of innate and acquired immunity. Of course, as with all aspects of the host immune response, some pathogens have turned autophagy to their advantage. For this volume, experts in the fields of bacteriology, virology, mycology, parasitology, immunology, and cell biology describe the cellular mechanisms of autophagosome formation and maturation, its contribution to host defenses, and the mechanisms pathogenic microbes have acquired to overcome and subvert this formidable barrier to infection. In addition, specialists discuss current efforts to exploit knowledge of the autophagy pathway to improve vaccine design. Accordingly, this thorough examination of an extraordinary cellular battleground between host and pathogen can stimulate ongoing research to understand and to manipulate autophagy to improve human health.

William T. Jackson
Michele S. Swanson

ACKNOWLEDGMENTS

The editors would like to thank the staff at Wiley-Blackwell, especially Mindy Okura-Marszycki for her efforts in getting this project off the ground, and Stephanie Dollan, Michelle Kwok, and Sangeetha Parthasarathy for helping us get it across the finish line. We are, of course, especially indebted to all of the chapter authors for their tremendous efforts throughout the process.

William T. Jackson
Michele S. Swanson

AUTOPHAGY AND IMMUNITY

Xu Liu and Daniel J. Klionsky

*Life Sciences Institute and Department of Molecular, Cellular and Developmental Biology,
University of Michigan, Ann Arbor, Michigan, USA*

1.1 INTRODUCTION

Autophagy is a highly controlled process in which cellular components are self-degraded and subsequently recycled. This pathway in part plays a “house cleaning” role in the cell, directing numerous cargoes to the lysosome (or the vacuole in yeast and plants) for degradation. Depending on the specific conditions, the cargoes include random portions of cytoplasm, protein aggregates, and damaged or superfluous organelles such as mitochondria and peroxisomes. Dysfunction of autophagy is linked with many pathologies, including cancer, diabetes, myopathies, heart, liver and lung diseases, and certain types of neurodegenerative disease (Castets et al., 2013; Gonzalez et al., 2011; Klionsky and Codogno, 2013; Murrow and Debnath, 2013; Rubinsztein et al., 2012; Yang and Klionsky, 2010).

Emerging studies have revealed that autophagy plays important roles in immunity. In 2004, independent studies demonstrated for the first time that invading pathogens can be cargoes for autophagy (Gutierrez et al., 2004; Nakagawa et al., 2004). Today it is well accepted that autophagy can directly eliminate intracellular pathogens, including bacteria, fungal parasites, and viruses. Autophagy can also activate innate immune signaling cascades such as Toll-like receptor (TLR) signaling to attack invading pathogens (Lee et al., 2007; Xu et al., 2007). However, microbes constantly undergo strong selective pressure to develop strategies to block host defense mechanisms. Indeed, studies indicate that some adaptations that confer pathogenicity involve microbial inactivation or subversion of

autophagy through distinct mechanisms (Deretic and Levine, 2009; Kuballa et al., 2012; Levine et al., 2011; Yuk et al., 2012; Zhou and Zhang, 2012).

Autophagy's role in immunity is not limited to controlling infection by direct elimination of pathogens. For example, autophagy facilitates MHC (major histocompatibility complex) antigen presentation, indicating that autophagy is involved in adaptive as well as innate immunity (English et al., 2009; Paludan et al., 2005). Moreover, defects in autophagy are associated with autoimmune diseases such as Crohn disease (Levine et al., 2011; Schroder and Tschopp, 2010; Shi et al., 2012). Thus, autophagy is an integral part of our response to infection and plays a key role in immunity. A comprehensive understanding of autophagy as it pertains to microbial infection and the molecular mechanisms that underlie the interplay between autophagy and immune signaling pathways may enable us to unravel the pathogenesis of many infectious and immune diseases, and develop more effective therapeutic strategies for their treatment.

1.2 AUTOPHAGY

1.2.1 Types of autophagy

There are three main types of autophagy: chaperone-mediated autophagy (CMA), microautophagy, and macroautophagy (Figure 1.1). CMA is a process where a cytosolic chaperone protein, HSPA8/HSC70, specifically recognizes its cargo proteins through a KFERQ-like




Figure 1.1. Schematic model of mammalian autophagy. Cargoes including cytosolic proteins, protein aggregates, and damaged organelles are sequestered by a phagophore, which will expand and mature to form a complete autophagosome. The outer membrane of the autophagosome fuses with either a late endosome (forming an amphisome, which then fuses with a lysosome) or lysosome, forming an autolysosome. Finally, the cargoes together with the inner membrane are degraded and the breakdown products are released back into the cytosol for reuse.

motif and facilitates their translocation directly across the lysosomal membrane for degradation (Dice, 2007; Kaushik and Cuervo, 2012). Microautophagy involves the uptake of portions of cytoplasm by the direct invagination or protrusion of the lysosomal or vacuolar membrane (Mijaljica et al., 2011). The third process, macroautophagy, hereafter referred to as autophagy, is the best characterized and will be the focus of this chapter.

1.2.2 Morphology

The morphological hallmark of autophagy involves the *de novo* formation of a double-membrane organelle named the autophagosome; however, this structure is essentially an end product of the sequestration process and as such is not really the primary functional unit of autophagy. Rather, the precursor to the autophagosome, the phagophore, is the dynamic membrane structure that is responsible for sequestering the cargos such as damaged organelles and invading pathogens (Figure 1.1). The phagophore expands with the addition of membrane, the sources of which are suggested to include almost every intracellular organelle. Upon completion, the phagophore seals and becomes a completed autophagosome. The autophagosome may fuse directly with a lysosome or, first, with a late endosome to form an intermediate amphisome. The subsequent fusion of the outer membrane of the autophagosome or the amphisome limiting membrane with a lysosome generates an autolysosome and exposes the cargoes to the degradative lysosomal enzymes. The degradation products, especially amino acids, are subsequently released back into the cytosol and are used in generating energy or as substrates for biosynthetic pathways.

1.2.3 Molecular machinery

Even though autophagosomes have been observed by electron microscopy as early as the 1950s, the molecular mechanisms of autophagy have been poorly studied until the past two decades (Stromhaug and Klionsky, 2001). The molecular machinery was first identified through studies in budding yeast, *Saccharomyces cerevisiae*, and to date more than 30 autophagy-related (*ATG*) genes have been identified as being involved in this process (Harding et al., 1995; Klionsky et al., 2003; Thumm et al., 1994; Tsukada and Ohsumi, 1993). Subsequent work with mammalian cells has revealed homologs of the core autophagy machinery (Xie and Klionsky, 2007), supporting the notion that autophagy is evolutionarily conserved. At the same time, there are also increasing numbers of *ATG* proteins being identified in mammals and other model systems such as *Caenorhabditis elegans* that lack yeast homologs, suggesting an increased complexity and diversity of function in higher eukaryotes (Klionsky and Codogno, 2013). For ease of discussion, the protein machinery of autophagy is subdivided into four major complexes in the following sections, and we focus on the mammalian autophagy machinery.

ULK1/ULK2 complex Autophagy occurs at a basal level in cells under normal conditions. Upon stress or other stimuli, autophagy can be induced, and defects in regulation that prevent proper induction can lead to aberrant cell physiology; however, too much autophagy activity can also be detrimental to the cell. Thus, the level of autophagy must be tightly controlled. Accordingly, there are various factors that regulate autophagy induction, and studies have shown that the ULK1/ULK2 (unc-51 like autophagy activating kinase 1/2) complex functions in part in an early stage of autophagy regulation.

ULK1 and ULK2 are kinases and the other components of the complex include ATG13, RB1CC1/FIP200 (RB1-inducible coiled-coil 1), and ATG101. ATG13 directly interacts

with ULK1/ULK2 and RB1CC1 regardless of the nutrient availability (Hosokawa et al., 2009; Jung et al., 2009); however, the phosphorylation status of these proteins changes under different conditions. In nutrient-rich conditions, a key upstream negative regulator of autophagy, the mechanistic target of rapamycin complex 1 (MTORC1) interacts with the complex and phosphorylates ULK1/ULK2 and ATG13, inhibiting ULK1/ULK2 kinase activity. Upon starvation, MTORC1 is released from the complex. ULK1/ULK2 and ATG13 are then partially dephosphorylated, leading to activation of ULK1/ULK2 kinase activity, which in turn leads to phosphorylation of ATG13 (presumably on distinct sites from those used by MTORC1) and RB1CC1 to induce autophagy (Chan, 2009; Hara et al., 2008; Hosokawa et al., 2009). AMPK (AMP-activated protein kinase) also binds ULK1/ULK2 and positively regulates autophagy through phosphorylation upon glucose starvation; as expected, AMPK and MTORC1 phosphorylate ULK1 at different sites (Kim et al., 2011; Zhao and Klionsky, 2011).

Class III phosphatidylinositol 3-kinase complexes The class III phosphatidylinositol 3-kinase (PtdIns3K) is generally thought to act downstream of the ULK1/ULK2 complex, mediating formation of phosphatidylinositol-3-phosphate (PtdIns3P) on the phagophore membrane, an event essential for autophagy. PtdIns3P serves to recruit downstream factors such as WIPI1 (WD repeat domain, phosphoinositide interacting 1) and WIPI2, which are involved in the trafficking of ATG9 and promote autophagosome maturation (Polson et al., 2010). In mammals, there are multiple class III PtdIns3K complexes with the core components being PIK3C3/VPS34 (phosphatidylinositol 3-kinase, catalytic subunit type 3), BECN1/Beclin 1 (beclin 1, autophagy related), and PIK3R4/VPS15/p150 (phosphoinositide-3-kinase, regulatory subunit 4). BECN1 can interact with several proteins, including AMBRA1 (autophagy/beclin-1 regulator 1), ATG14/ATG14L/Barkor, UVRAG (UV radiation resistance associated), KIAA0226/Rubicon and BCL2 (B-cell CLL/lymphoma 2) to form distinct complexes (Furuya et al., 2005; Itakura et al., 2008; Matsunaga et al., 2009; Petiot, 2000). BECN1 was first identified as a BCL2 binding protein. The interaction between BECN1 and BCL2 inhibits the binding of the former with PIK3C3, thus inhibiting autophagy. The ATG14–BECN1–PIK3C3–PIK3R4–AMBRA1 complex is specific for autophagy; ATG14 may direct this complex to the phagophore to promote autophagosome biogenesis (Itakura et al., 2008; Matsunaga et al., 2009), whereas the SH3GLB1 (SH3-domain GRB2-like endophilin B1)–UVRAG–BECN1–PIK3C3–PIK3R4 complex functions at a later step to promote autophagosome maturation (Itakura et al., 2008). In contrast, the KIAA0226–UVRAG–BECN1–PIK3C3–PIK3R4 complex localizes to late endosomes and negatively regulates autophagosome maturation (Matsunaga et al., 2009).

ATG9 trafficking system The Atg9 trafficking system is best characterized in yeast, although even in that model organism there are many questions that remain to be answered. The current model is that the transmembrane protein Atg9 cycles between the phagophore assembly site (PAS) and peripheral (i.e., non-PAS) sites, and that this process is needed for the proper delivery of membrane from various donor organelles to the expanding phagophore (Noda et al., 2000; Reggiori et al., 2005). Atg23 and Atg27 interact with Atg9 and facilitate its anterograde traffic from the peripheral sites to the PAS, whereas Atg2–Atg18 and the Atg1–Atg13 complex (yeast homolog of the ULK1/ULK2 complex) are required for its retrograde transport from the PAS back to the peripheral sites (Guan et al., 2001; Reggiori et al., 2004; Wang et al., 2001; Yen et al., 2007).

In mammals, ATG9 localizes to the *trans*-Golgi network and endosomes in nutrient-rich conditions. A pool of ATG9 translocates to MAP1LC3 (microtubule-associated protein 1 light chain 3)/LC3-positive compartments upon starvation. This translocation is dependent on ULK1 and PIK3C3 kinase activity (Young et al., 2006). The dynamic movement between ATG9 and the phagophore membrane during autophagy suggests a conserved role for ATG9 in membrane movement during phagophore expansion. Similar to yeast, ATG9 retrieval from the phagophore membrane is dependent on WIPI2, a homolog of yeast Atg18, but movement in this direction is ULK1 kinase independent (Orsi et al., 2012).

Ubiquitin-like conjugation systems There are two ubiquitin-like (Ubl) conjugation systems, which involve the Ubl proteins ATG12 and LC3. These systems are quite well-studied, playing important roles in phagophore expansion and maturation (Ichimura et al., 2000; Mizushima et al., 1998, 2001). ATG12 is conjugated with ATG5 in a manner that is similar to canonical ubiquitination (Mizushima et al., 1998). The E1-like enzyme ATG7 activates ATG12 via a thioester bond (Tanida et al., 2001). ATG12 is then transferred to an E2-like enzyme, ATG10, before it is finally conjugated to an internal lysine of ATG5. ATG5 then noncovalently binds ATG16L1 (autophagy related 16-like 1 (*S. cerevisiae*)), which subsequently dimerizes. During autophagy, ATG5 directs the ATG12—ATG5—ATG16L1 complex to the phagophore (Mizushima, 2003).

The different isoforms of LC3 (and the related GABARAP (GABA(A) receptor-associated protein) subfamily proteins) are conjugated to the lipid phosphatidylethanolamine (PE), and this modification is required for association with the phagophore membrane (Kabeya et al., 2004; Tanida et al., 2003). Initially, the cysteine protease ATG4B removes the C-terminal amino acids of pro-LC3 to reveal a glycine residue, generating a cytosolic form named LC3-I. LC3-I is then sequentially activated by ATG7 and conjugated via the E2-like enzyme ATG3, resulting in the membrane-associated form, LC3-II (Tanida et al., 2001, 2002). The PE group can ultimately be cleaved by ATG4B in a deconjugation step, which is important for maintaining the proper level of autophagy activity (Tanida et al., 2006).

1.2.4 Physiological roles

Autophagy has many physiological roles. First, autophagy is a protective mechanism against cellular stress (Kuma et al., 2004; Yang and Klionsky, 2010). For example, autophagy's role in supplying essential building blocks or metabolic substrates such as amino acids under conditions of nutrient deprivation is critical for maintaining cell viability under adverse conditions; autophagic degradation and recycling enable cells to maintain the synthesis of essential proteins and to generate ATP.

Recent studies indicate that autophagy is also indispensable during development. One example of such a role is seen after oocyte fertilization in *C. elegans*, where autophagy is involved in the elimination of maternal mitochondria (Al Rawi et al., 2011; Sato and Sato, 2011); however, this does not appear to be the case in mammals (Luo et al., 2013). In addition, during embryonic development, clearance of apoptotic cells is achieved through autophagy (Qu et al., 2007). Autophagy is also implicated in life span extension; induction of autophagy increases longevity in several model organisms (Rubinsztein et al., 2011) and its role in clearing aggregate-prone proteins and damaged mitochondria might be relevant to its antiaging effects.

As autophagy acts to eliminate many harmful components in a cell, malfunction of autophagy has also been suggested to correlate with or be the cause of a variety of diseases, such as cancer, neurodegeneration, cardiovascular myopathies, and lysosomal storage disorders (Klionsky and Codogno, 2013). For example, the selective degradation of damaged mitochondria is suggested to underlie the tumor suppressive effects of autophagy, possibly through reducing oxidative stress and preventing DNA damage (Narendra et al., 2008). Several lines of evidence suggest that the role of autophagy in clearing toxic aggregate-prone proteins is critical to prevent certain types of neurodegeneration, including those associated with Huntington, Alzheimer, and Parkinson diseases (Bjørkøy et al., 2005; Ravikumar et al., 2002).

1.3 AUTOPHAGY AND IMMUNITY

1.3.1 Xenophagy: autophagic clearance of intracellular microorganisms

For decades, scientists have explored how our body fights against invading pathogens. Even though an understanding of our immune systems has steadily increased, a major problem, how a cell breaks down an intracellular pathogen without harming itself, has been overlooked or at least unanswered. Only recently have researchers realized that autophagy plays a vital role in this process. This specific type of autophagy is termed “xenophagy.”

Autophagic degradation of bacteria and parasites Several independent studies have revealed that xenophagy acts to eliminate many different bacteria and other microbes (Levine et al., 2011; Yuk et al., 2012). A good example of parasite clearance is seen with *Toxoplasma gondii* (Andrade et al., 2006). This parasite is able to survive within macrophages by residing in parasitophorous vacuoles that are modified to avoid fusion with lysosomes. However, stimulation of *T. gondii*-infected macrophages with CD40 (CD40 molecule, TNF receptor superfamily member 5), a member of the TNF (tumor necrosis factor) receptor superfamily, causes colocalization of parasitophorous vacuoles and LC3. Conversely, treatment of infected cells with the autophagy inhibitor 3-methyladenine (3-MA) or knockdown of BECN1 blocks the fusion of parasitophorous vacuoles with lysosomal compartments (Andrade et al., 2006). Thus, these results suggest that phagophores capture parasites that are residing within these vacuoles and direct them to the lysosome for degradation.

As for bacterial clearance, evidence indicates that autophagosomes can sequester both bacteria that reside within membranous compartments and those present free within the cytosol, through mechanisms that are overlapping, but distinct (Figure 1.2) (Levine and Deretic, 2007). The clearance of *Mycobacterium tuberculosis* is a good example of engulfment of bacteria residing within phagosomes (Gutierrez et al., 2004). After entering the cell through endocytosis, *M. tuberculosis* can actively survive in a host cell and evade the host defense by inhibiting phagosomal maturation. However, if autophagy is induced by either nitrogen starvation or rapamycin treatment, the inhibition of phagosomal maturation by *M. tuberculosis* is suppressed and intracellular bacterial survival is significantly decreased. Also, a substantial colocalization of *M. tuberculosis*-containing phagosomes with autophagosomes is observed upon autophagy induction, supporting the idea that phagophores capture bacteria residing within phagosomes and target them to lysosomal compartments for degradation (Gutierrez et al., 2004).




Figure 1.2. Models of autophagic elimination of invading pathogens. Intracellular virus proteins are recognized by autophagy receptors and recruited to autophagosomes by interaction between the receptors and LC3. Both bacteria within phagosomes and bacteria that have escaped from phagosomes can be degraded through autophagy. Bacteria residing in a phagosome can be engulfed by a phagophore; after completion of sequestration, the resulting autophagosome then fuses with a lysosome forming an autophagolysosome. (Note that we strongly recommend that this term be reserved to describe the compartment that results from the fusion of lysosomes with autophagosomes containing phagosomes, and not for the compartments that result from the fusion of other autophagosomes with lysosomes, which are termed autolysosomes.) Some bacteria are able to damage the phagosomal membrane and escape into the host cell cytoplasm. These cytosolic bacteria are polyubiquitinated and recognized by autophagy receptor proteins, directing their delivery to phagophores.

With regard to cytosolic bacteria, a major problem/challenge is that these microbes need to be specifically recognized and distinguished from other “self” endomembranes, including their endosymbiotic descendants, the mitochondria. Starvation-induced autophagy is usually nonselective, but there are also selective types of autophagy. Recent studies of selective autophagy reveal a common cargo–ligand–receptor–scaffold model (Mijaljica et al., 2012). A receptor protein recognizes ligands on cargoes and at the same time binds the scaffold protein of the autophagy machinery, selectively targeting cargoes into the autophagy pathway. Specific receptors have been identified that recognize intracellular bacteria during xenophagy, including SQSTM1/p62 (sequestome 1), NBR1 (neighbor of BRCA1 gene 1), CALCOCO2/NDP52 (calcium binding and coiled-coil domain 2) and OPTN (optineurin) (Kraft et al., 2010; Thurston et al., 2009; Wild et al., 2011; Zheng et al., 2009). Usually, cytosolic intracellular bacteria are coated with polyubiquitin, and these receptors are able to simultaneously bind the ubiquitinated bacteria and LC3, linking the cargo with the autophagy machinery. In this way, intracellular bacteria are specifically targeted for degradation.

Despite the utility of xenophagy in degrading intracellular bacteria, certain pathogens have been successful in developing strategies for evading autophagy. One example of such evasion is seen with *Listeria monocytogenes* (Birmingham et al., 2007). After infection of its host macrophages, a population of *L. monocytogenes* damages phagosomes and is released into the cytosol, where they will ultimately be recognized by autophagy. However, the expression of the virulence factor ActA triggers host cell actin polymerization. This provides the bacteria with actin-based motility, which allows cell-to-cell spread and avoidance of autophagic degradation.

Autophagic elimination of viruses The cargo of xenophagy is not restricted to protozoan parasites and bacteria; autophagy can also capture invading viruses. In general, the mechanism involved in the recognition of viruses and their sequestration by phagophores is conceptually similar to that of cytosolic bacteria (Figure 1.2). For example, after Sindbis virus infects the mouse central nervous system, SQSTM1 interacts with Sindbis virus capsid proteins, mediating their further degradation through autophagy (Orvedahl et al., 2010). This action significantly reduces virally-induced cell death.

Similar to bacteria, many viruses also act to inhibit autophagy to confer virulence. First, numerous viruses can either inhibit antiviral signaling pathways that induce autophagy or they can activate an autophagy inhibitory pathway. EIF2AK2/PKR (eukaryotic translation initiation factor 2- α kinase 2) is an interferon-inducible double-stranded RNA sensor that mediates overall downregulation of translation in host cells via phosphorylation of EIF2A (eukaryotic translation initiation factor 2A, 65 kDa). This signaling pathway also positively regulates virus-induced autophagy (Levine and Deretic, 2007). Viruses develop multiple strategies to block the EIF2AK2 pathway. For example, during infection herpes simplex virus type 1 (HSV-1) expresses the US11 protein to antagonize EIF2AK2-mediated phosphorylation of EIF2A by binding to the kinase, thus preventing autophagy induction (Lussignol et al., 2013). As discussed above, MTOR signaling is a negative regulator of autophagy. Upon infecting dendritic cells, human immunodeficiency virus-1 (HIV-1) downregulates autophagy by inducing MTOR and RPS6KB/p70 S6 kinase (ribosomal protein S6 kinase, 70 kDa) activation, thus promoting viral proliferation in host cells (Blanchet et al., 2010).

In addition, a virulence factor may also directly target the autophagy machinery to negatively regulate autophagy. For example, the HSV-1 protein ICP34.5 binds BECN1 to block autophagy, possibly through inhibiting PIK3C3 kinase activity (Orvedahl et al., 2007).